Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan:63:103184.
doi: 10.1016/j.ebiom.2020.103184. Epub 2021 Jan 6.

How to select cancer patients for immunotherapy

Per Pfeiffer  1 , Camilla Qvortrup  2 , Karin Holmskov Hansen  3
Affiliations

How to select cancer patients for immunotherapy

Per Pfeiffer et al. EBioMedicine. 2021 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr. Qvortrup reports grants from Servier, grants from Pierre-Fabre, personal fees from PledPharma, personal fees from Roche, personal fees from Merck, other from Incyte, other from Bayer, outside the submitted work; Dr. Hansen and Prof. Pfeiffer have nothing to disclose.

Similar articles

See all similar articles

Cited by

References

    1. Zhao B., Zhao H., Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol. 2020;12:1–22. doi: 10.1177/1758835920937612. - DOI - PMC - PubMed
    1. Zou Y., Hu X., Zheng S. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours. EBioMedicine. 2020 doi: 10.1016/j.ebiom.2020.103137. - DOI - PMC - PubMed
    1. Duffy M.J., Crown J. Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin Chem. 2019:1228–1238. doi: 10.1373/clinchem.2019.303644. - DOI - PubMed
    1. Shen X., Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362:k3529. - PMC - PubMed
    1. Lee C.C., Soon Y.Y., Lum J.H.Y., Tan C.L., Tey J.C.S. Frequency of discordance in programmed death-ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: a systematic review and meta-analysis. Acta Oncol. 2020;59:696–704. doi: 10.1080/0284186x.2020.1741678. - DOI - PubMed

MeSH terms

Substances